Albion Financial Group UT Purchases 506 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Albion Financial Group UT boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 182.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 783 shares of the biopharmaceutical company’s stock after acquiring an additional 506 shares during the quarter. Albion Financial Group UT’s holdings in Gilead Sciences were worth $72,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Advisory Alpha LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $260,000. XML Financial LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $203,000. Genesis Private Wealth LLC bought a new position in Gilead Sciences in the 4th quarter valued at approximately $362,000. Simon Quick Advisors LLC boosted its position in Gilead Sciences by 24.7% in the fourth quarter. Simon Quick Advisors LLC now owns 6,120 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 1,214 shares in the last quarter. Finally, MCF Advisors LLC grew its stake in shares of Gilead Sciences by 45.2% during the fourth quarter. MCF Advisors LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 2,111 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on GILD. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective for the company. Piper Sandler lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Barclays upped their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Trading Up 0.1 %

GILD opened at $93.04 on Thursday. The company has a market cap of $115.95 billion, a P/E ratio of 1,033.78, a price-to-earnings-growth ratio of 1.29 and a beta of 0.18. The company has a fifty day moving average price of $91.62 and a two-hundred day moving average price of $84.57. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company posted $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.